Holt J A, Bolanos J
Clin Chem. 1986 Oct;32(10):1836-43.
We tested whether a newly available enzyme-linked immunoassay (EIA) validly measures estrogen receptor (ER) in gynecologic tumors. We first documented that ER so measured agreed with results by established radioligand-based assays [dextran-coated charcoal (DCC) and hydroxylapatite (HAP)] for in-house breast carcinomas and for proficiency testing specimens. Then, for gynecologic tumors, we found strong correlations between results for ER as measured by the two methods; e.g., for 27 ovarian carcinomas, r greater than or equal to 0.86. The same was true for ER measured in nine specimens of ovarian carcinoma from women who had undergone chemotherapy: r greater than or equal to 0.94. Radioinert estradiol or serum had no discernible effect on EIA measurements of ER, whereas our DCC assay was rendered uninterpretable. Evidently the EIA validly measures ER in steroidogenic tissues, including ovarian, and also in breast and uterine carcinomas. Clinical management of the latter is now based in part on results of steroid receptor assays. For ovarian carcinomas, ER assay can be helpful for determining the probable primary site of adenocarcinomas of unknown origin, and it is providing a rational basis for development of new diagnostic and therapeutic strategies.
我们测试了一种新可用的酶联免疫吸附测定（EIA）是否能有效地检测妇科肿瘤中的雌激素受体（ER）。我们首先记录到，通过这种方法检测的ER与基于放射性配体的既定检测方法[葡聚糖包被活性炭（DCC）和羟基磷灰石（HAP）]对内部乳腺癌和能力验证标本的检测结果一致。然后，对于妇科肿瘤，我们发现两种方法检测的ER结果之间存在很强的相关性；例如，对于27例卵巢癌，r大于或等于0.86。对于接受过化疗的女性的9份卵巢癌标本中检测的ER也是如此：r大于或等于0.94。放射性惰性雌二醇或血清对ER的EIA测量没有明显影响，而我们的DCC检测结果无法解读。显然，EIA能有效地检测包括卵巢在内的类固醇生成组织中的ER，也能检测乳腺癌和子宫癌中的ER。后者的临床管理现在部分基于类固醇受体检测的结果。对于卵巢癌，ER检测有助于确定不明来源腺癌的可能原发部位，并且为新的诊断和治疗策略的开发提供了合理依据。
